Chief Science Officer

About Us

Red Arrow Therapeutics spun out of the University of Tokyo in 2021 to save patients' lives with the power of pH-sensitive nanopolymer drug delivery technology. We have raised $8.5M as of end of Aug 2024, and our first pipeline aims to deliver IL-12 for solid tumor treatment.

‍

Role Overview

We are currently looking for a fractional CSO who aligns with the company vision, can lead the scientific story creation, and evangelize it to potential investors in tandem with the CEO.

‍

Responsibilities

• Expected commitment: 2,3 hours a week
• With the CEO, communicate with potential investors on the development story of our lead compound, from preclinical to early clinical
• Lead creation of the preclinical development strategy, including efficacy and safety studies. These include IND-required studies and may include value generation studies for fundraising.
• Communicate with CROs to execute above studies. (Note: actual protocol creation can be done by CROs and external pharmacology/tox consultants)
• Interpret study results and update the development story/strategy
• Communicate with the discovery research and CMC team and incorporate such aspects into the development strategy

‍

Qualifications

• PhD in a relevant field
• 10+ years work experience in preclinical/translational research in the immuno-oncology field
• Work experience in a start-up environment

‍

Preferred Skills

• 20+ years work experience in preclinical/translational research in the immuno-oncology field
• Work experience in a pharma environment
• Experience of contributing to fundraising efforts at a start-up in the US

‍

How to Apply

Note: This is a syndicated job post, meaning it was not posted to Fractional Jobs directly, so we don't have control over the application process. To apply, click on the "View Application" and follow the application's instructions.